Mallinckrodt emerges from bankruptcyIn connection with Mallinckrodt's emergence, David Stetson, executive chairman of Alpha Metallurgical Resources, and Jon Zinman, a managing director at Silver Point Capital, have been appointed to the board, effective immediately. Upsher-Smith intros generic LivaloUpsher-Smith offers strengths of Pitavastatin tablets in 1 mg, 2 mg and 4 mg. Glenmark obtains FDA nod for generic Prolixin Fluphenazine is a medication that treats mental health conditions that cause disruptive thoughts and nervousness. Teva intros generic Livalo Pitavastatin tablets are a prescription medicine used along with a heart-healthy diet to help lower “bad” cholesterol in certain adults. ERISA Industry Committee urges Ohio legislature to recognize value of biosimilars The ERISA Industry Committee has submitted a comment letter to the Ohio House of Representatives Insurance Committee urging the panel to amend House Bill 291 to include access to all biosimilar products. Surescripts acquires ActiveRADAR ActiveRADAR offers evidence-based, formulary-specific and medically accepted use-specific therapeutic alternatives. Alembic unveils 2 generics Alembic is launching generic Robinul and generic Adrucil. U.S. District Court dismisses Norwich’s lawsuit against the FDA over generic Xifaxan Norwich asked the District Court to direct the FDA in granting immediate approval for generic Xifaxan (rifaximin) 550 mg. FDA approves Amgen’s Wezlana biosimilar Wezlana is used to treat multiple inflammatory diseases. Theravance, Mylan settle patent litigation with Teva over Yupelri Teva has been granted a royalty-free, non-exclusive license to market generic Yupelri in the United States on or after April 23, 2039. First Previous 49 50 51 52 53 Next Last
